Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Retained Earnings (2019 - 2025)

Historic Retained Earnings for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$1.9 billion.

  • Beam Therapeutics' Retained Earnings fell 2666.67% to -$1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 billion, marking a year-over-year decrease of 2666.67%. This contributed to the annual value of -$1.6 billion for FY2024, which is 3166.19% down from last year.
  • Beam Therapeutics' Retained Earnings amounted to -$1.9 billion in Q3 2025, which was down 2666.67% from -$1.8 billion recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Retained Earnings peaked at -$599.2 million during Q1 2021, and registered a low of -$1.9 billion during Q3 2025.
  • For the 5-year period, Beam Therapeutics' Retained Earnings averaged around -$1.2 billion, with its median value being -$1.2 billion (2023).
  • Per our database at Business Quant, Beam Therapeutics' Retained Earnings crashed by 15661.45% in 2021 and then tumbled by 833.33% in 2024.
  • Beam Therapeutics' Retained Earnings (Quarter) stood at -$768.3 million in 2021, then crashed by 37.63% to -$1.1 billion in 2022, then fell by 12.53% to -$1.2 billion in 2023, then tumbled by 31.66% to -$1.6 billion in 2024, then fell by 21.28% to -$1.9 billion in 2025.
  • Its Retained Earnings stands at -$1.9 billion for Q3 2025, versus -$1.8 billion for Q2 2025 and -$1.7 billion for Q1 2025.